New cancer drug enters first human safety tests
NCT ID NCT07016490
Summary
This is a very early-stage study to find a safe dose and learn how the body processes a new experimental drug called SSGJ-709. It will involve about 15 adults with advanced cancers that have not responded to standard treatments. The main goal is to check for side effects and see how the drug behaves in the body, while also looking for any early signs that it might help shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Southern Oncology Clinical Research Unit (SOCRU)
RECRUITINGAdelaide, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.